Editorial: Autologous and Allogeneic Stem Cell Transplant in Cancer Therapy

Over the last 10 to 20 years, there have been significant improvements in the fields of both autologous and allogenic transplantation [...].

[1]  C. Mølgaard,et al.  Physical Fitness and Frailty in Males after Allogeneic Hematopoietic Stem Cell Transplantation in Childhood: A Long-Term Follow-Up Study , 2022, Cancers.

[2]  Ø. Bruserud,et al.  Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients , 2022, Cancers.

[3]  C. Solano,et al.  Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience , 2022, Cancers.

[4]  D. Benson,et al.  Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience , 2022, Cancers.

[5]  A. Piekarska,et al.  BKV Related Hemorrhagic Cystitis—An Insight into Risk Factors and Later Complications—An Analysis on Behalf of Polish Adult Leukemia Group , 2022, Cancers.

[6]  D. Benson,et al.  Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience , 2021, Cancers.

[7]  R. Wäsch,et al.  Allogeneic Stem Cell Transplantation in Multiple Myeloma , 2021, Cancers.

[8]  Qiuhong Zhao,et al.  Letermovir Prophylaxis and Cytomegalovirus Reactivation in Adult Hematopoietic Cell Transplant Recipients with and without Acute Graft Versus Host Disease , 2021, Cancers.

[9]  H. Goldschmidt,et al.  Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma , 2021, Cancers.

[10]  A. Mackey,et al.  Cardiorespiratory fitness and physical performance after childhood hematopoietic stem cell transplantation: a systematic review and meta-analysis , 2021, Bone Marrow Transplantation.

[11]  A. Nagler,et al.  Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia , 2021, Cancers.

[12]  S. Montoto,et al.  Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. , 2021, The Lancet. Haematology.

[13]  D. Benson,et al.  Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation , 2019, Cancers.

[14]  J. Esteve,et al.  Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years , 2020, Clinical Cancer Research.

[15]  J. Esteve,et al.  Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT , 2018, British journal of haematology.

[16]  Ø. Bruserud,et al.  Patients with Treatment-Requiring Chronic Graft versus Host Disease after Allogeneic Stem Cell Transplantation Have Altered Metabolic Profiles due to the Disease and Immunosuppressive Therapy: Potential Implication for Biomarkers , 2018, Front. Immunol..

[17]  Ø. Bruserud,et al.  Metabolic Serum Profiles for Patients Receiving Allogeneic Stem Cell Transplantation: The Pretransplant Profile Differs for Patients with and without Posttransplant Capillary Leak Syndrome , 2015, Disease markers.

[18]  J. Scarisbrick,et al.  A multicentre UK study of GVHD following DLI: Rates of GVHD are high but mortality from GVHD is infrequent , 2015, Bone Marrow Transplantation.

[19]  Ø. Bruserud,et al.  Preconditioning Serum Levels of Endothelial Cell-Derived Molecules and the Risk of Posttransplant Complications in Patients Treated with Allogeneic Stem Cell Transplantation , 2014, Journal of transplantation.

[20]  Carmen L. Wilson,et al.  Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: a report from the St Jude Lifetime cohort study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Robison,et al.  Pulmonary complications in survivors of childhood and adolescent cancer , 2002, Cancer.

[22]  V. Kuenen-Boumeester,et al.  Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. , 2000, Blood.